BSX241220C92000
- 0.20
- -0.15-42.86%
Boston Scientific Newsroom
Boston Scientific Analyst Ratings
Truist Financial Maintains Boston Scientific(BSX.US) With Buy Rating, Announces Target Price $110
RBC Raises Price Target on Boston Scientific to $105 From $98, Keeps Outperform Rating
Morgan Stanley Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $100
Boston Scientific Analyst Ratings
JP Morgan Maintains Overweight on Boston Scientific, Raises Price Target to $110
Goldman Sachs Raises Price Target on Boston Scientific to $103 From $102, Maintains Buy Rating
Boston Scientific Is Maintained at Buy by TD Cowen
Boston Scientific Analyst Ratings
TD Cowen Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $110
TD Cowen Adjusts Price Target on Boston Scientific to $110 From $100, Maintains Buy Rating
Citigroup Adjusts Boston Scientific Price Target to $107 From $98, Maintains Buy Rating
Boston Scientific Is Maintained at Overweight by Wells Fargo
Boston Scientific Analyst Ratings
Wells Fargo Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $100
Citi Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $107
Wells Fargo Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $98
Boston Scientific's Promising Clinical Trials and Innovative Approaches Justify Buy Rating
Boston Scientific Analyst Ratings
Canaccord Genuity Adjusts Price Target on Boston Scientific to $101 From $98, Keeps Buy Rating